2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina

The HERe2Cure project, which involved a group of breast cancer experts, members of multidisciplinary tumor boards from healthcare institutions in Bosnia and Herzegovina, was initiated with the aim of defining an optimal approach to the diagnosis and treatment of HER2 positive breast cancer. After individual multidisciplinary consensus meetings were held in all oncology centers in Bosnia and Herzegovina, a final consensus meeting was held in order to reconcile the final conclusions discussed in individual meetings. Guidelines were adopted by consensus, based on the presentations and suggestions of experts, which were first discussed in a panel discussion and then agreed electronically between all the authors mentioned. The conclusions of the panel discussion represent the consensus of experts in the field of breast cancer diagnosis and treatment in Bosnia and Herzegovina. The objectives of the guidelines include the standardization, harmonization and optimization of the procedures for the diagnosis, treatment and monitoring of patients with HER2-positive breast cancer, all of which should lead to an improvement in the quality of health care of mentioned patients. The initial treatment plan for patients with HER2-positive breast cancer must be made by a multidisciplinary tumor board comprised of at least: a medical oncologist, a pathologist, a radiologist, a surgeon, and a radiation oncologist/radiotherapist

2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina.

The HERe2cure project, which involved a group of breast cancer experts, members of multidisciplinary tumor boards from healthcare institutions in Bosnia and Herzegovina, was initiated with the aim of defining an optimal approach to the diagnosis and treatment of HER2 positive breast cancer. After individual multidisciplinary consensus meetings were held in all oncology centers in Bosnia and Herzegovina, a final consensus meeting was held in order to reconcile the final conclusions discussed in individual meetings. Guidelines were adopted by consensus, based on the presentations and suggestions of experts, which were first discussed in a panel discussion and then agreed electronically between all the authors mentioned. The conclusions of the panel discussion represent the consensus of experts in the field of breast cancer diagnosis and treatment in Bosnia and Herzegovina. The objectives of the guidelines include the standardization, harmonization and optimization of the procedures for the diagnosis, treatment and monitoring of patients with HER2-positive breast cancer, all of which should lead to an improvement in the quality of health care of mentioned patients. The initial treatment plan for patients with HER2-positive breast cancer must be made by a multidisciplinary tumor board comprised of at least: a medical oncologist, a pathologist, a radiologist, a surgeon, and a radiation oncologist/radiotherapist

Epidemiološke i patohistološke karakteristike neoplazmi testisa u Zeničko-dobojskom kantonu, Bosna i Hercegovina: trogodišnja monocentrična studija

Aim: The primary aim of the study was to determine the incidence of testicular neoplasms in the Zenica-Doboj Canton (ZDC) region for the period from 2019 to 2021. Also, the study aimed to examine the age structure of the affected population, the frequency of testicular neoplasms in all the ZDC cities and municipalities, and the pathohistological characteristics of neoplasms. Material and methods: The study was conducted at the Oncology and Radiotherapy Department of the Zenica Cantonal Hospital. The study period refers to the time interval from January 2019 to December 2021. The study included 37 patients with a verified diagnosis of testicular neoplasm. Results: Arithmetic mean of patients’ age was 33.49 years, while the standard deviation was 12.59. Most respondents, accounting for 40.5%, were aged 26-35 years. The incidence of testicular neoplasms in the ZDC region was 4.2/100,000 persons in 2019, 3.08/100,000 persons in 2020, and 3.10/100,000 persons in 2021. Most diagnosed neoplasms (48.6%) were the myxoid type germ cell originating tumors. Conclusion: The incidence of testicular neoplasms in the ZDC was 4.2/100,000 persons in 2019, 3.08/100,000 persons in 2020, and 3.10/100,000 persons in 2021.Cilj: Osnovni cilj istraživanja je utvrditi incidenciju neoplazmi testisa na području Zeničko-dobojskog kantona za razdoblje od 2019. do 2021. godine. Također, cilj je bio ispitati dobnu strukturu oboljele populacije, učestalost neoplazme testisa u svim gradovima Zeničko-dobojskog kantona, te patohistološke karakteristike neoplazmi. Materijal i metode: Istraživanje je provedeno na Odjelu za onkologiju i radioterapiju Kantonalne bolnice Zenica. Razdoblje pregleda odnosi se na vremenski interval od liječnja 2019. do prosinca 2021. Istraživanjem je obuhvaćeno 37 ispitanika s verificiranom dijagnozom neoplazme testisa. Rezultati: Aritmetička sredina bolesničkih godina bila je 33,49, a standardna devijacija 12,59. Najveći broj ispitanika pripada dobnoj kategoriji od 26-35 godina, u postotku od 40,5%. Učestalost novotvorina testisa na području Zeničko-dobojskog kantona za 2019. godinu iznosila je 4,2/100.000 stanovnika, za 2020. godinu 3,08/100.000 stanovnika, a za 2021. godinu 3,10/100.000 stanovnika. Većina dijagnosticiranih novotvorina bila je miksoidnog tipa, podrijetlom iz spolnih stanica (48,6%). Zaključak: Učestalost novotvorina testisa na području Zeničko-dobojskog kantona u 2019. godini iznosila je 4,2/100.000 stanovnika, u 2020. godini 3,08/100.000 stanovnika, a u 2021. godini 3,10/100.000 stanovnika